Ganli Pharmaceutical: GLR1062 injection has received a notice of approval for clinical trials of drugs.

Ganli Pharmaceutical announced that it has recently received the "Drug Clinical Trial Approval Notification Letter" from the National Medical Products Administration for the investigational drug GLR1062 injection. The acceptance number is CXSL2600087 and the notification number is 2026LP01171. The product is named GLR1062 injection, in the form of an injection, classified as a Class 1 therapeutic biological product. The application is for domestic drug production registration - clinical trial application, with indication for age-related macular degeneration in adults. The approval allows for the clinical trial of this product in treating age-related macular degeneration in adults.